Abstract
This chapter describes the various issues a formulator of biologics faces when turning an active pharmaceutical ingredient (API) into a biopharmaceutical product that can be administered to a patient. A well-equipped analytical lab to characterize chemical and physical characteristics of the protein in the formulation process is a first requirement. Then, the proper excipients and conditions (e.g., freeze-dried or not; refrigerated or not) to achieve an acceptable shelf-life of the formulated protein can be selected. Throughout this process one should consider the specific requirements linked to the desired route of administration, e.g., dose, volume, primary container. Alternative routes of administration are briefly discussed and their limitations listed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arakawa T, Kita Y, Carpenter JF (1991) Protein-solvent interactions in pharmaceutical formulation. Pharm Res 8:285–291
Bahrenburg S, Karow AR, Garidel P (2015) Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications. Biotechnol J 10:610–622
Chang BS, Hershenson S (2002) Practical approaches to protein formulation development. In: Carpenter JF, Manning MC (eds) Rational design of stable protein formulations–theory and practice. Kluwer Academic/Plenum, New York, pp 1–20
Chi E, Krishnan S, Randolph TW, Carpenter JF (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20:1325–1336
Constantino HR, Pikal MJ (2004) Lyophilization of biopharmaceuticals. AAPS Press, Arlington
Geidobler R, Winter G (2013) Controlled ice nucleation in the field of freeze-drying: fundamentals and technology review. Eur J Pharm Biopharm 85:214–222
Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler H-C, Jiskoot W (2012) Forced degradation of therapeutic proteins. J Pharm Sci 101:895–913
Heilmann K (1984) Therapeutic systems. Rate controlled delivery: concept and development. Georg Thieme Verlag, Stuttgart
Hizentra Infusion Guide. https://www.hizentra.com/common/pdf/Hizentra-Step-by-step-infusion-guide.pdf. Accessed Nov 2017
Hovorka R (2011) Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 7:385–395
Jiskoot W, Crommelin DJA (2005) Methods for structural analysis of protein pharmaceuticals. AAPS Press, Arlington
Jiskoot W, Nejadnik MR, Sediq AS (2017) Potential issues with the handling of biologicals in a hospital. J Pharm Sci 106:1688–1689
Jorgensen J, Nielsen HM (eds) (2009) Delivery technologies for biopharmaceuticals: peptides, proteins, nucleic acids and vaccines. Wiley, Chichester
Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB (2011) Protein–excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63:1118–1159
Kinnunen HM, Mrsny RJ (2014) Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. J Control Release 182:22–32
Maberly GF, Wait GA, Kilpatrick JA, Loten EG, Gain KR, Stewart RDH, Eastman CJ (1982) Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient. Diabetologia 23:333–336
Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS (2010) Stability of protein pharmaceuticals: an update. Pharm Res 27:544–575
Manning MC, Patel K, Borchardt RT (1989) Stability of proteins. Pharm Res 6:903–918
Martos A, Koch W, Jiskoot W, Wuchner K, Winter G, Friess W, Hawe A (2017) Trends on analytical characterization of polysorbates and their degradation products in biopharmaceutical formulations. J Pharm Sci 106:1722–1735
Mensink MA, Frijlink HW, van der Voort Maarschalk K, Hinrichs W (2017) How sugars protect proteins in the solid state and during drying (review): mechanisms of stabilization in relation to stress conditions. Eur J Pharm Biopharm 114:288–295
Moeller EH, Jorgensen L (2009) Alternative routes of administration for systemic delivery of protein pharmaceuticals. Drug Discov Today Technol 5:89–94
Nejadnik MR, Randolph TW, Volkin DB, Schöneich C, Carpenter JF, Crommelin DJA, Jiskoot W (2018) Post-production handling and administration of protein pharmaceuticals and potential instability issues. J Pharm Sci 107(8):2013–2019
Nguyen TH, Ward C (1993) Stability characterization and formulation development of alteplase, a recombinant tissue plasminogen activator. In: Wang YJ, Pearlman R (eds) Stability and characterization of protein and peptide drugs. Case histories. Plenum Press, New York, pp 91–134
Patton JS, Bukar JG, Eldon MA (2004) Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43:781–801
Pearlman R, Bewley TA (1993) Stability and characterization of human growth hormone. In: Wang YJ, Pearlman R (eds) Stability and characterization of protein and peptide drugs. Case histories. Plenum Press, New York, pp 1–58
Pikal MJ (1990) Freeze-drying of proteins. Part I: process design. BioPharm 3:18–27
Pristoupil TI (1985) Haemoglobin lyophilized with sucrose: effect of residual moisture on storage. Haematologia 18:45–52
Richter WF, Bhansali SG, Morris ME (2012) Mechanistic determinants of biotherapeutics absorption following sc administration. AAPS J 14:559–570
Runge A, Brown A (2016) https://diatribe.org/fda-approval-medtronic-minimed-670g-hybrid-closed-loop-system
Sacha GA, Saffell-Clemmer W, Abram K, Akers MJ (2010) Practical fundamentals of glass, rubber, and plastic sterile packaging systems. Pharm Dev Technol 15(1):6–34. https://doi.org/10.3109/10837450903511178
Sacha G, Rogers JA, Miller RL (2015) Pre-filled syringes: a review of the history, manufacturing and challenges. Pharm Dev Technol 20:1–11. https://doi.org/10.3109/10837450.2014.982825
Schaepelynck P, Darmon P, Molines L, Jannot-Lamotte MF, Treglia C, Raccah D (2011) Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps. Diabetes Metab 37:S85–S93
Schersch K, Betz O, Garidel P, Muehlau S, Bassarab S, Winter G (2010) Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins I: stability after freeze-drying. J Pharm Sci 99:2256–2278
Sediq AS, van Duijvenvoorde RB, Jiskoot W, Nejadnik MR (2016) Subvisible particle formation during stirring. J Pharm Sci 105:519–529
Supersaxo A, Hein WR, Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7:167–169
Tomlinson E (1987) Theory and practice of site-specific drug delivery. Adv Drug Deliv Rev 1:87–198
Trevitt S, Simpson S, Wood A (2016) Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 10:714–723
Vemuri S, Yu CT, Roosdorp N (1993) Formulation and stability of recombinant alpha1-antitrypsin. In: Wang YJ, Pearlman R (eds) Stability and characterization of protein and peptide drugs. Plenum Press, New York, pp 263–286
Vlieland ND, Gardarsdottir H, Bouvy ML, Egberts TCG, van den Bemt BJF (2016) The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology 55:704–709
Vlieland ND, Nejadnik MR, Gardarsdottir H, Romeijn AS, Sediq S, Bouvy ML, Egberts ACG, van den Bemt BJF, Jiskoot W (2018) The impact of inadequate temperature storage conditions on aggregate and particle formation in drugs containing tumor necrosis factor-alpha inhibitors. Pharm Res 35:42
Weinbuch D, Hawe A, Jiskoot W, Friess W (2018) In: Mahler HC, Warne NW (eds) Challenges in protein product development. AAPS advances in the pharmaceutical sciences series. AAPS Press/Springer, New York, pp 3–22
Zbacnik TJ, Holcomb RE, Katayama DS, Murphy BM, Payne RW, Coccaro RC, Evans GJ, Matsuura JE, Henry CS, Manning MC (2017) Role of buffers in protein formulations. J Pharm Sci 106:713–733
Zölls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, Hawe A (2012) Particles in therapeutic protein formulations–part I. Overview of analytical methods. J Pharm Sci 101:914–935
Further Reading
Carpenter JF, Manning MC (2002) Rational design of stable protein formulations–theory and practice. Kluwer Academic/Plenum, New York
Mahler H-C, Jiskoot W (2012) Analysis of aggregates and particles in protein pharmaceuticals. Wiley, Hoboken
Mahler HC, Warne NW (2018) Challenges in protein product development. AAPS advances in the pharmaceutical sciences series. AAPS Press/Springer, New York, p 2018
Manning MC, Liu J, Li T, Holcomb RE (2018) Rational design of liquid formulations of proteins. Adv Protein Chem Struct Biol 112:1–59
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Crommelin, D.J.A., Hawe, A., Jiskoot, W. (2019). Formulation of Biologics Including Biopharmaceutical Considerations. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-030-00710-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-00710-2_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-00709-6
Online ISBN: 978-3-030-00710-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)